anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention concerns a sensor that, when exposed to a fluid, develops a measurable characteristic that is a function of the level of an analyte in the fluid and of a calibration quantity of the sensor. A calibration quantity is some physical, chemical or other inherent property that the sensor possesses that affects its response to the analyte. The sensor includes an RFID tag that receives, stores and conveys information representing the calibration quantity. The wireless device is incorporated into or attached to the sensor during the manufacturing process and before the sensor is calibrated. The wireless device can be written wirelessly once the calibration has been done. This does not involve any additional handling of the sensor and can be done once the sensor has been placed into a protective enclosure. Because of this, the process of wirelessly transmitting the calibration information to the wireless device does not alter any pre-existing calibration quantities and neither does it introduce any new calibration quantities, thus preserving the calibration of the sensor even though the sensor has been wirelessly modified to carry information representing its calibration quantity.
PURPOSE:To obtain a skin external preparation capable of preventing the skin from aging by normalizing the skin function such as water holding ability of the skin or turnover of a skin keratinous cell layer. CONSTITUTION:This skin external preparation comprises a membrane-coating granule (MCG) as an active ingredient in an amount of 0.01-10wt.%, preferably 0.1-1wt.% in the preparation. The transepidermal water loss of the aged skin such as roughened skin or xeroderma is reduced by applying the MCG to the skin to restore the water holding function and further normalize the delayed turnover of the keratinous cell layer. Thereby, the skin can be improved into an excellent state thereof. The MCG is obtained as an extract separated from the mammalian skin with water or an organic solvent or a purified extract thereof. For example, the epidermis of the mammalian skin is peeled and the peeled epidermal cell is then ground to destroy the cell membrane. Precipitates of uncrushed cells or nuclei are subsequently removed by a method such as centrifugation to afford the purified MCG.
Acquisition equipment：SAGA high-density electromyography system (TMSi, New Zealand).Acquisition site: paravertebral muscle at the L1-L3 level, with the electrode sheet placed 1.5 cm adjacent to the spinous process.Acquisition process: ① Place the electrode sheet and fix it. ② The subject was instructed to complete the specified movements according to the experimental paradigm and the EMG signals were recorded simultaneously.Experimental Paradigm:Biering-Sorensen test,BST：The subject was lying prone on the bed, with the upper half of the body poking out of the bed, the anterior superior iliac spine located at the edge of the bed, both lower limbs partially immobilized on the bed with straps, both hands crossed in front of the chest grasping the contralateral shoulder and tightly pressed against the chest wall, and the torso was suspended in the air and parallel to the floor, and the patient stopped the test when he/she maintained this position for 90s.
Participants will discuss the results of their CAT-MH, BAM, and PSS with a coach trained in motivational interviewing with 14 days of study randomization. Based on these results, the coach will help to identify behavior change goals, resolve ambivalence, amplify activation, explore their options, and empower the participant toward taking action to obtain appropriate support services tailored to their individual issues and concerns. The number of RME sessions will range from 1-3, determined by the participant's level of activation and desire to engage in additional sessions, as well as the number of challenges identified in their initial session or determined by their CAT-MH results. Participants will be sent a link at the end of week 1 with the aim to complete an action plan questionnaire, in which they will be asked to describe up to 3 action plan goals (in mental health, social services, and stress reduction/mental wellness categories).
This is a single-arm study involving 1 year of follow-up. Study intervention involves a one-time administration of Urolift prior to SBRT for prostate cancer treatment.
The purpose of Cardiac resynchronization therapy (CRT) is to send small amounts of energy (called pacing) through the wires to both the left and right lower chambers of your heart at (or near) the same time. This helps the heart pump in a more coordinated way and send more blood to your body with each beat. How much energy is used for pacing is called the stimulus intensity. Increasing the pacing stimulus intensity of the left ventricular wire can lead to an increase in the volume of heart muscle directly stimulated. This has previously been shown to produce beneficial effects on the heart function, like strength of contraction and increased volume of blood pumped. The purpose of this study is to determine if pacing the wires in the left ventricular chamber of the heart using higher stimulus intensity improves the strength of the heart's contraction.
A closed system transfer device (CSTD) and vial assembly machine includes a linear travel assembly including a linear mount, and an actuator operably coupled to the linear mount. The linear mount is movable in an axial direction between a first position and a second position spaced from the first position. A CSTD fixture is configured to be removably coupleable to the linear mount. A vial mount is disposed adjacent to a portion of the linear travel assembly. A vial fixture is configured to be removably coupleable to the vial mount. The vial fixture is sized to hold a vial in axial alignment with a portion of the CSTD fixture when the vial fixture is coupled to the vial mount and the CSTD fixture is coupled to the linear mount. When the linear mount moves from the first position to the second position, the linear mount moves relative to the vial mount.
1314428 Pyridine substituted chromenols BEECHAM GROUP Ltd 26 April 1971 [11 May 1970] 11307/71 Headings C2C and C2P Novel substituted chromenols of the Formula (I) and non-toxic acid addition salts, wherein R 1  is C 1-6  alkyl, R 2  is C 1-20  alkyl or C 3-8  cycloalkyl- C 1-20 -alkyl, and X is an optionally substituted etherified or esterified hydroxyl group (exeluding amino acid esters) may be obtained by conventional esterification or etherification of a chromenol of Formula I in which X is OH. Examples of X are acyloxy, e.g. acetoxy, hemisuccinate ester, ethyl carbonate ester, diethylaminoethyl ether, alkyl ether, e.g. methyl ether, monophosphate ester or carbamate ester groups. Thus compounds in which X is an ester group, such as acyloxy, may be formed by reacting the chromenol with a mono or polybasic organic or inorganic acid or its acid halide or anhydride. Compounds in which X is an etherified hydroxy group may be obtained from a compound in which X is OH or ONa by reaction with an alkylhalide or, e.g. diethylaminoethyl halide. Where X is a phosphate ester, a compound where X is OH is reacted with Cl.P(O)(OCH 2 C 6 H 5 ) 2  to form an intermediate [X=-O-P(O)(OCH 2 C 6 H) 2 ] which is catalytically hydrogenated to yield a compound in which X is -OP(O)(OH) 2  which can be obtained in Na salt form. Pharmaceutical compositions, useful as antidepressants, anti-anxiety agents, hypotensives and analgesics, comprise compounds of Formula (I) above together with pharmaceutical diluents in forms suitable for administration orally or by injection.
9-ING-41 is a small molecule potent selective GSK-3β inhibitor with antitumor activity. It acts through downregulation of NF-κB and decreases the expression NF-κB target genes cyclin D1, Bcl-2, anti-apoptotic protein (XIAP) and B-cell lymphoma-extra large (Bcl-XL) leading to inhibition of tumor growth in multiple solid tumor cell and lymphoma lines and patient derived xenograft (PDX) models. 9-ING-41 may also function as an immune modulatory agent by decreasing checkpoint expression and enhancement of T-cell / NK-cell effector function. This is a phase 2, open-label, non-randomized, single institution study investigating the novel glycogen synthase kinase-3 beta (GSK-3β) inhibitor 9-ING-41 in combination with carboplatin chemotherapy in patients with incurable, recurrent or metastatic salivary gland carcinomas (SGC). The safety of this combination has been established in the Actuate 1801 study. Thirty-one evaluable patients with advanced SGC (including all histologic subtypes and adenoid cystic carcinoma \[ACC\]) will receive 9-ING-41 intravenously (IV) along with carboplatin IV at standard dosing together on Day 1, and 9-ING-41 alone on Day 4 of a 21-day cycle. Participants will be enrolled to two histologic cohorts: Cohort 1 will be comprised of those with ACC, and Cohort 2 will include patients with non-ACC SGC (or all other salivary gland cancer histologies). Treatment will continue until progression of disease, death, or discontinuation of therapy for any reason.

The primary aim of the study is to assess the overall response rate (ORR) as defined by RECIST v1.1 in the overall study population (including both Cohorts 1 and 2). Secondary aims include assessing progression-free survival (PFS), overall survival (OS), determining safety and tolerability, measuring patient-reported quality of life metrics, and correlating efficacy with molecular and immunologic predictors of response. We hypothesize that the novel combination of a GSK-3β inhibitor with carboplatin chemotherapy will result in an ORR of 25% or greater in this patient population where no approved therapies have been established.
A tissue culture system for epitheliating or endotheliating and functional examination and delivering of synthetic or natural hollow organs in controlled sterile conditions for surgical implantation, is new.  A tissue culture system for epitheliating or endotheliating and functional examination and delivering of synthetic or natural hollow organs in controlled sterile conditions for surgical implantation, is new. The hollow organ is arranged in a first tube. One end of the organ is connected to a canule. The first tube is placed in a second tube to form a chamber. The first tube has holes in contact with the chamber. Tubes circulate gases and patient serum through the chamber. Nutrients and cells are supplied to the first tube and metabolized wastes are removed.
Interleukin-36 (IL-36) cytokines are structurally similar to other Interleukin-1 superfamily members and are essential to convey inflammatory responses at epithelial barriers including the skin, lung, and gut. Due to their potent effects on immune cells, IL-36 cytokine activation is regulated on multiple levels, from expression and activation to receptor binding. Different IL-36 isoforms convey specific responses as a consequence of particular danger- or pathogen-associated molecular patterns. IL-36 expression and activation are regulated by exogenous pathogens, including fungi, viruses and bacteria but also by endogenous factors such as antimicrobial peptides or cytokines. Processing of IL-36 into potent bioactive forms is necessary for host protection but can elevate tissue damage. Indeed, exacerbated IL-36 signalling and hyperactivation are linked to the pathogenesis of diseases such as plaque and pustular psoriasis, emphasising the importance of understanding the molecular aspects regulating IL-36 activation. Here, we summarise facets of the electrochemical properties, regulation of extracellular cleavage by various proteases and receptor signalling of the pro-inflammatory and anti-inflammatory IL-36 family members. Additionally, this intriguing cytokine subfamily displays many characteristics that are unique from prototypical members of the IL-1 family and these key distinctions are outlined here.
Both arms will undergo 8-weeks of Mindfulness-Based Stress Reduction (MBSR) training. The experimental arm will be randomly assigned to practice meditation immediately following the emotional stress task in the lab during the post-MBSR lab visit.
PURPOSE: To obtain a detergent compsn. which is lowly irritative, is excellent in foaming power, foam quality, and foam breaking, gives a good feeling of refreshment during rinsing and after cleaning, and is esp. excellent in freedom from creaking during rinsing and feeling of being stretched after cleaning. CONSTITUTION: This detergent compsn. contains an N-alkyl or -alkenylcitramide represented by the formula (wherein R is a 10-20C satd. or unsatd. hydrocarbon group; and M is H, an alkali or alkaline earth metal, ammonium, or an alkanolamine) and a higher fatty acid.
Unembellished white tablets. The drug should be taken one hour before bedtime. Total treatment duration will be 6 weeks.
The present invention belongs to the technical field of biological engineering pharmacy or the medicine field of the class of protein polypeptide, and concretely relates to an efficient blood vessel generating inhibitor, a production method and application thereof. The present invention designs the efficient blood vessel generating inhibitor RGD-ED with integrin affinity. The inhibitor comprises blood vessel generating inhibition polypeptide isoleucine-valine-arginine-arginine-alanine-aspartic acid-arginine-alanine-alanine-valine-proline; the polypeptide with an arginine-glycine-aspartic acid sequence is connected with one end or both ends respectively. The RGD-ED of the present invention can be synthesized. The present invention also expresses one kind of RGD-ED in colibacillus by a genetic engineering method for the separation, the dissolution, the renaturation and the ion exchange chromatographic separation and purification of inclusion body protein to obtain the RGD-ED. A product can obviously enhance the effects of inhibiting the growth of esoderma cells, inhibiting the generation of neogenesis blood vessels and resisting tumours of the existing blood vessel generating inhibitor in an experiment in a body and an experiment outside the body. The present invention can be used as therapeutic medicine of solid tumours and rheumatoid arthritis.
Due to limited samples, no genetic loci have been identified for obsessive-compulsive disorder (OCD) in genome-wide association studies. Additionally, although co-morbidities between OCD and schizophrenia (SCZ) were observed, their common genetic etiology was not completely known. Here, we conducted a comprehensive investigation regarding the genetic architecture of OCD and the common genetic foundation shared by OCD and SCZ using summary statistics data (2688 cases and 7037 controls for OCD; 53,386 cases and 77,258 controls for SCZ). We discovered significant genetic correlation between OCD and SCZ (r̂g=0.296, P = 2.82 × 10-11). We then performed two multi-trait association analyses to detect OCD-associated loci and colocalization analysis to detect causal variants. Parallel gene-level analyses were also implemented. We identified 323 OCD-relevant variants located within 12 loci, with four loci shared the same causal variants between OCD and SCZ. Further, the gene-level analyses discovered 8 OCD-associated genes. Finally, multiple functional analyses at both SNP and gene levels showed that these genetic association signals had significant enrichments in the regions of left ventricle and anterior cingulate cortex, and suggested an important role of pathways involving regulation of telomere maintenance, histone phosphorylation, and GnRH secretion. Overall, this study identified new genetic loci for OCD and provided substantial evidence supporting common genetic foundation underlying OCD and SCZ. The findings advanced our understanding of genetic architecture and pathophysiology of OCD as well as shedding light on shared genetic etiology of the two disorders.
The study was planned as a randomized controlled study. Workers between the ages of 18-60 who are working in a heat treatment factory in izmir and experiencing non-specific neck pain will be included in the study. The factory workers included in the study will be divided into three by simple random method. The groups will be called chiropractic, placebo and control groups. All participants will be given ergonomic training before the treatment. The chiropractic group will be applied 2 days a week. The placebo group will also be applied sham manipulation 2 days a week. No intervention will be made in the control group. In order to collect data from the participants; Visual Analog Scale, Neck Disability Questionnaire and Bournemouth will be used for pain and pain-related dysfunctions, and Pittsburgh Sleep Quality Questionnaire will be used to determine sleep quality. These questionnaires will be repeated before starting the study and at the end of the study.
BACKGROUND: Dose escalation with brachytherapy after pelvic irradiation is standard for treating cervical cancer. Its application can be impossible for some patients. Dose escalation with SBRT is widely used with high local control and acceptable toxicity rates in different body parts. The study enrolled patients who underwent SBRT treatment for dose escalation in the cervix.
METHODS: Patients who were pathologically diagnosed and treated with cervical SBRT after definitive CRT were included in the study. A total of 30 Gy in 5 fractions for the high-risk volume was prescribed. The first response evaluation was performed three months after the completion of treatment. Treatment toxicity was documented according to the RTOG-EORTC scale. Oncological outcomes and toxicity were assessed.
RESULTS: Between 02.2019 and 05.2023, 40 patients were treated with an SBRT boost after pelvic irradiation. The median follow-up time was 16 months (7-44 months). The median HR CTV was 47 cc (8,3-168,2 cc). There were 39 patients who achieved a complete response and one who achieved a partial response in the third month after treatment. There were two local or two regional recurrences. The 1-year metastasis-free survival was 88%, and the 1-year progression-free survival was 88%. During the follow-up period, one grade 3 gastrointestinal side effect was observed.
CONCLUSIONS: SBRT which has low toxicity and reasonable locoregional control rates in a short follow-up period, may be an option for dose escalation in brachytherapy-ineligible cervical cancer patients.
OBJECTIVE: Gastric cancer (GC) is one of the most prevalent malignant tumors of the digestive system. The advanced metastasis of gastric cancer severely limits the conventional approaches for its treatment, while certain traditional Chinese medicinal compounds have been reported to possess promising abilities in inhibiting tumor metastasis. Such as Poria (PA), known as Fu Ling in Chinese, is a commonly used traditional Chinese medicinal herb derived from Poria cocos, a fungus belonging to the polyporaceae family.
METHODS: The proliferation capacity of cells was measured using the MTT assay, while the invasion and migration abilities of cells after treatment with different concentrations of PA were evaluated through wound healing assay and Transwell assay. The differential expression of mRNA was analyzed using qPCR. The in vivo growth of tumors was assessed by subcutaneous tumor formation in mice.
RESULTS: Both in vivo and in vitro experiments have demonstrated that PA significantly inhibits the proliferation of GC. Moreover, in vitro experiments have revealed that PA not only suppresses the invasion and migration of GC cells but also reverses TNF-β-induced EMT. Further experiments have revealed that PA inhibits cell invasion, migration and EMT by inducing ferroptosis in GC cells.
CONCLUSION: In brief, the present study shows that PA inhibits tumor metastasis by inducing ferroptosis in GC cells. Our findings suggest that PA may have therapeutic potential in GC.
BACKGROUND: This study presents minimum 6-year follow-up data on the survival and satisfaction of an uncemented modular revision femoral system, following on from our previously published earlier results.
METHODS: We retrospectively reviewed all revision hip arthroplasties performed at our institution between January 2005 and October 2012, using a single modular femoral revision system. Patient-reported outcomes were collected (satisfaction score and Oxford Hip Score). Preoperative and postoperative radiographs were reviewed for stem subsidence, and Kaplan-Meier analysis was performed for survival. A total of 115 femoral revisions were performed in 106 patients.
RESULTS: All-cause survival was 82% (95% confidence interval 74 to 91%) at 10.8 years, and 96% (95% confidence interval 90 to 100%) excluding septic failure. Of the 19 cases requiring reoperation, 16 were for infection, 2 for aseptic loosening, and 1 for mechanical failure. At final follow-up, 88.5% of patients were "satisfied" or "very satisfied".
CONCLUSIONS: This study showed excellent clinical results of a commonly used revision hip stem with at least 10 years follow-up. Satisfaction rates were high, with few aseptic failures. Stem subsidence was more common in revisions for infection, but did not correlate with lower satisfaction scores.
The invention discloses a peptide targeting cancer stem cells and application thereof, and particularly relates to a synthetic peptide targeting cancer stem cells. The peptide consists of any amino acid sequence from SEQ ID NO. 1 to SEQ ID NO. 15. Also disclosed is a composition comprising the synthetic peptide having a therapeutic agent conjugated thereto, and a pharmaceutically acceptable carrier or diluent. The present invention also discloses a method for screening peptides specifically binding to cancer stem cells, comprising establishing an oligo peptide library by using a phage expression system, contacting phages in the oligo peptide library with a culture of general cancer cells of a cancer cell line, contacting phages that do not bind to the general cancer cells with a culture of cancer stem cells of the cancer cell line, and screening out peptides specifically binding to cancer stem cells from the phages that bind to the cancer stem cells.
<P>PROBLEM TO BE SOLVED: To solve problems that almost conventional medicines for stupe for analgesic and antiphlogistic purposes are based on exothermic effect of Guinea pepper essence, have low persistency of effect and irritating feeling in bathing and can not be used in operation under direct sunlight.  <P>SOLUTION: This medicine for stupe consisting essentially of garlic is developed by noticing that garlic has pharmacological actions such as fatigue recovery effect by activation of metabolism and amelioration of blood circulation, sterilization action, sedation action, heat insulation action, and the like. Using 1-menthol eliminates a smell characteristic of garlic. It is confirmed that the use of the medicine for stupe using garlic has high analgesic and antiphlogistic action, immediate effect and persistency of effect. The medicine for stupe has no irritating feeling at the attached part in bathing and is used under direct sunlight.  <P>COPYRIGHT: (C)2006,JPO&NCIPI